Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 21 02 2024
revised: 08 04 2024
accepted: 11 04 2024
medline: 27 4 2024
pubmed: 27 4 2024
entrez: 27 4 2024
Statut: epublish

Résumé

Interstitial lung diseases (ILDs) are characterized by inflammation or fibrosis of the pulmonary parenchyma. Despite the involvement of immune cells and soluble mediators in pulmonary fibrosis, the influence of antimicrobial peptides (AMPs) remains underexplored. These effector molecules display a range of activities, which include immunomodulation and wound repair. Here, we investigate the role of AMPs in the development of fibrosis in ILD. We compare the concentration of different AMPs and different cytokines in 46 fibrotic (F-ILD) and 17 non-fibrotic (NF-ILD) patients by ELISA and using peripheral blood mononuclear cells from in vitro stimulation in the presence of lysozyme or secretory leukocyte protease inhibitor (SLPI) from 10 healthy donors. We observed that bronchoalveolar lavage (BAL) levels of AMPs were decreased in F-ILD patients (lysozyme:

Identifiants

pubmed: 38673881
pii: ijms25084297
doi: 10.3390/ijms25084297
pii:
doi:

Substances chimiques

Muramidase EC 3.2.1.17
Secretory Leukocyte Peptidase Inhibitor 0
SLPI protein, human 0
Cytokines 0
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Auteurs

Rubén Osuna-Gómez (R)

Inflammatory Diseases, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain.

Maria Mulet (M)

Inflammatory Diseases, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain.

Silvia Barril (S)

Respiratory Department, Institut de Recerca Biomèdica de Lleida (IRBLleida), Hospital Universitari Arnau de Vilanova-Santa María, Translational Research in Respiratory Medicine, Universitat de Lleida (UdL), 25198 Lleida, Spain.
Department of Respiratory, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Elisabet Cantó (E)

Inflammatory Diseases, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain.

Paloma Millan-Billi (P)

Department of Respiratory, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Department of Respiratory, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain.

Ana Pardessus (A)

Department of Respiratory, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

David de la Rosa-Carrillo (D)

Department of Respiratory, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Diego Castillo (D)

Department of Respiratory, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Silvia Vidal (S)

Inflammatory Diseases, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH